stoxline Quote Chart Rank Option Currency Glossary
  
Pulse Biosciences, Inc. (PLSE)
8.71  0.31 (3.69%)    03-28 16:00
Open: 8.75
High: 9.085
Volume: 270,153
  
Pre. Close: 8.4
Low: 8.57
Market Cap: 479(M)
Technical analysis
2024-03-28 4:53:38 PM
Short term     
Mid term     
Targets 6-month :  11.94 1-year :  13.59
Resists First :  10.22 Second :  11.64
Pivot price 9.55
Supports First :  7.92 Second :  6.59
MAs MA(5) :  8.57 MA(20) :  9.55
MA(100) :  8.96 MA(250) :  7.15
MACD MACD :  -0.3 Signal :  -0.1
%K %D K(14,3) :  11.5 D(3) :  7.5
RSI RSI(14): 42.7
52-week High :  13.61 Low :  2.49
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PLSE ] has closed above bottom band by 25.0%. Bollinger Bands are 1.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 9.1 - 9.14 9.14 - 9.18
Low: 8.47 - 8.51 8.51 - 8.56
Close: 8.63 - 8.71 8.71 - 8.78
Company Description

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Headline News

Thu, 28 Mar 2024
Pulse Biosciences files for $50M mixed securities shelf (NASDAQ:PLSE) - Seeking Alpha

Thu, 28 Mar 2024
Pulse Biosciences Inc (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023 - GuruFocus.com

Thu, 28 Mar 2024
Pulse Biosciences to initiate rights offering (NASDAQ:PLSE) - Seeking Alpha

Thu, 28 Mar 2024
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results - Business Wire

Thu, 28 Mar 2024
Pulse Biosciences Announces Plans to Initiate a Rights Offering - Business Wire

Mon, 11 Mar 2024
Where Does Pulse Biosciences Inc (PLSE) Stock Fall in the Medical Instruments & Supplies Field After It Is Up 11.70% This Week? - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Instruments & Supplies
Shares Out 0 (M)
Shares Float 55 (M)
Held by Insiders 1.627e+007 (%)
Held by Institutions 70.5 (%)
Shares Short 2,630 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.855e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 442 %
Return on Assets (ttm) 66.6 %
Return on Equity (ttm) -32.5 %
Qtrly Rev. Growth -9000 %
Gross Profit (p.s.) 0
Sales Per Share -80.09
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -34 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.11
Price to Cash Flow 15.49
Stock Dividends
Dividend 0
Forward Dividend 2.57e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android